- Home
- SVRE vs CYCN Comparison
SVRE vs CYCN Comparison
Compare SVRE & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVRE | CYCN |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 16.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SVRE | CYCN |
|---|---|---|
| Price | $2.19 | $23.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.1K | ★ 114.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | $1,793.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $0.55 | $1.03 |
| 52 Week High | $6.30 | $8.48 |
Technical Indicators
Market Signals| Indicator | SVRE | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 41.06 |
| Support Level | $2.02 | $3.04 |
| Resistance Level | $3.33 | $3.42 |
| Average True Range (ATR) | 0.31 | 0.49 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 2.49 | 23.67 |
Price Performance
Historical ComparisonAbout SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.